|
Best Pharmaceuticals for Children Act (BPCA) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
This working group supports the goals of the Best Pharmaceuticals for Children Act (BPCA). The BPCA seeks to improve the level of information—in scientific publications and on the label—about pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations and publish a list of drugs/needs in pediatric therapeutics.
|
|
Biological Select Agents and Toxins Interagency Policy Committee (BSAT IPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Coordinating group with senior level leadership from CDC, FDA, and NIH that discusses appropriate oversight of Select Agents and Toxins.
|
|
Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-IPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Coordinating sub-group of FDA, CDC, and NIH staff that discuss the appropriate oversight of Select Agents and Toxins. This is a Subcommittee of the Biological Select Agents and Toxins Policy Coordination Committee (BSAT PPC).
|
|
Bioresource Development, Validation Tools, and Integrating High-Throughput Screening Technology Standards in Complementary and Alternative Medicine (CAM) Product Use in Children
|
Research Initiative
|
CDC, HRSA, SAMHSA
|
NCCIH, NICHD
|
Collaborative efforts between the FDA and NIH for substantiating health benefit claims for probiotics under Investigational New Drug Applications (IND) were placed in the framework of U01 Cooperative Agreements that began in 2008. The successful evaluation of the initiative has recently developed into an invitation to develop a Memorandum of Understanding (MoU) to promote resource sharing and exchange of research expertise; development of demonstration project(s); and the initiation of trans-agency research initiatives focused on the integration of advanced molecular technologies that lead to harmonization standards and improved diagnostics for safety and substantiation of the health benefits of probiotic interventions. In 2011, a collaboration with FDA was initiated to expand the validation tool. In 2012, a Materials Transfer Agreement [MTA] was approved and the FDA received the entire data collection to undergo testing employing their novel microarray multi-loci sequence testing system [MLST].
|
|
Blood Products Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
CC, NHLBI
|
The FDA Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs of its findings.
|
|
Blood, Organ, and Tissue Safety Committee (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
CC, NHLBI
|
The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from HHS organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the OASH Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director.
|
|
Board of Scientific Counselors of the CDC''s National Center of Injury Prevention and Control
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, SAMHSA
|
NICHD, NIA, NIDA, NIMH
|
The BSC advises the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCIPC regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention.
|
|
Botulism Guidelines Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC
|
The NIH Clinical Center is participating in a working group with CDC to develop clinical guidelines for treatment of botulism and use of botulism antitoxin.
|
|
Brain Attack Coalition
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NINDS
|
The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke.
|
|
Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative
|
Research Initiative
|
FDA
|
NINDS, NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought.
|